key: cord-1036362-k9sjdggy
authors: Abobaker, Anis; Idris, Mohamed Akasha; Ogunjimi, Olajide
title: A localised vasculitic-like skin rash following the second dose of COVID-19 vaccine
date: 2021-11-03
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.11.001
sha: ee391306ac6cf217b9d91987b71c9cd3104450b6
doc_id: 1036362
cord_uid: k9sjdggy

nan

rate 15, oxygen saturation 98% on room air, temperature 36.2, blood pressure 118/59 and pulse 87). Physical exam revealed red, raised, palpable and non-blanchable skin rash (most likely purpuric rash) localised mainly on the extensor surface of both legs (figure 1). The rash does not extend beyond the knee level, and no rash was seen elsewhere on the body. The rest of the physical exam was normal. Urine dipstick did not show any evidence of proteinuria or haematuria. No signs of lung cavitation or haemorrhage on chest X-ray. Blood work-up including full blood count, urea and electrolytes, liver function test, C-reactive protein, coagulation profile and vasculitis screen were unremarkable. The patient was discharged home 24-hour after the hospital admission on a short course of oral prednisolone.

Unlike our case who developed a purpuric rash, a petechial rash has been reported one day following the first dose of Sinovac COVID vaccine [Cebeci et al., 2021] . In fact, a generalised purpuric skin rash in association with thrombocytopenia has been reported in a 60-year-old male patient few days after receiving the first dose of Moderna vaccine [Malayala et al., 2021] . In our case the purpuric skin rash was localised to the lower limbs, and the platelet count was normal. Interestingly, two patients developed systemic vasculitis affecting the kidneys after the first dose of Mederna vaccine [Anderegg et al., 2021] . In our case however we believe that the patient developed a post-vaccination localised cutaneous vasculitic-like reaction. In conclusion, the main learning points from our case is; firstly, localised cutaneous vasculitic-like reaction on the non-injected limbs without associated systemic manifestations might be considered as a possible side effect of AstraZeneca vaccine.

Secondly, this skin reaction can develop after the second dose even with no history of previously reported dermatological reactions following the administration of the first dose.

Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia

De novo vasculitis after mRNA-1273 (Moderna) vaccination

Petechial skin rash associated with CoronaVac vaccination: first cutaneous side effect report before phase 3 results

Morbilliform rash after administration of Pfizer-BioNTech COVID-19 mRNA vaccine

Purpuric Rash and Thrombocytopenia After the mRNA-1273 (Moderna) COVID-19 Vaccine

 Figure 1 : Purpuric skin rash on both legs developed following the second dose of AstraZeneca vaccine

The authors declare that they have no conflict of interest Funding: No financial or nonfinancial benefits have been received or will be received from any party related directly or indirectly to the subject of this article Acknowledgment: The patient in this manuscript has given a written informed consent to the publication of her clinical case details.